Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14655765 | 0.93 | — | — | |
| SCHEMBL6301516 | 0.85 | L3MBTL1 (0.33) | MEN1KMT2A | |
| SCHEMBL3242097 | 0.83 | KDM4E (0.35) | — | |
| SCHEMBL3239940 | 0.81 | KDM4E (0.31) | — | |
| SCHEMBL45521 | 0.80 | LMNA (0.33) | — | |
| SCHEMBL6889106 | 0.78 | L3MBTL1 (0.33) | KMT2A | |
| SCHEMBL6301520 | 0.77 | L3MBTL1 (0.33) | KMT2A | |
| SCHEMBL1797106 | 0.77 | LMNA (0.39) | MEN1KMT2A | |
| SCHEMBL137086 | 0.76 | LMNA (0.31) | — | |
| SCHEMBL3242102 | 0.76 | LMNA (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174045-B2 | Benzopyrylium compounds | PIERCE BIOTECHNOLOGY, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| EP-2850078-B1 | BENZOPYRYLIUM COMPOUNDS | PIERCE BIOTECHNOLOGY INC (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20180002340-A1 | BENZOPYRYLIUM COMPOUNDS | PIERCE BIOTECHNOLOGY, INC. | 2018-01-04 | — | — | US | disclosed |
| US-9676787-B2 | Benzopyrylium compounds | PIERCE BIOTECHNOLOGY, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170152267-A9 | BENZOPYRYLIUM COMPOUNDS | DYOMICS GMBH (DE) | 2017-06-01 | — | — | US | disclosed |
| US-20150322078-A1 | BENZOPYRYLIUM COMPOUNDS | DYOMICS GMBH (DE) | 2015-11-12 | — | — | US | disclosed |
| EP-2850078-A1 | BENZOPYRYLIUM COMPOUNDS | Pierce Biotechnology, Inc. (US) | 2015-03-25 | — | — | EP | disclosed |
| WO-2014035712-A1 | BENZOPYRYLIUM COMPOUNDS | PIERCE BIOTECHNOLOGY, INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| US-6924372-B2 | Benzopyrylo-polymethine-based hydrophilic markers | DYOMICS GMBH (DE) | 2005-08-02 | — | — | US | disclosed |
| US-20040162423-A1 | Benzopyrylo-polymethine-based hydrophilic markers | DYOMICS GMBH (DE) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152267-A9 | BENZOPYRYLIUM COMPOUNDS | PABPC4, SSBP1, RBBP5 | MEN1 2192/4885KMT2A 3196/4885 |
| US-20150322078-A1 | BENZOPYRYLIUM COMPOUNDS | PABPC4, SSBP1, RBBP5 | MEN1 2192/4885KMT2A 3196/4885 |
| US-10174045-B2 | Benzopyrylium compounds | PABPC4, SSBP1, RBBP5 | MEN1 2192/4885KMT2A 3196/4885 |
| US-20180002340-A1 | BENZOPYRYLIUM COMPOUNDS | PABPC4, SSBP1, RBBP5 | MEN1 2192/4885KMT2A 3196/4885 |
| US-20040162423-A1 | Benzopyrylo-polymethine-based hydrophilic markers | EPCAM, CD68, CD44 | MEN1 3692/4885KMT2A 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.